What happened
The FDA approved a supplement for the Alinity m HR HPV assay covering self-collected vaginal specimens obtained in a healthcare setting. The assay detects HPV types associated with cervical pre-cancer and cancer risk.
Why it matters
Self-collection inside a clinic is less disruptive than home collection, but it can still reduce barriers for people who cannot undergo or decline cervical sampling. It also expands the evidence and infrastructure supporting more flexible screening models.
What to watch
Implementation in screening programs, staff training, patient preference, follow-up adherence and performance across different collection devices and populations.
